Designing liposomes as vaccine adjuvants

Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines

Volumn , Issue , 2013, Pages 181-203

  Henriksen Lacey, Malou ^a   Perrie, Yvonne ^b  

^a CIC BIOMAGUNE   (Spain)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944270830     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5070-2_10     Document Type: Chapter

References (51)

1. Agger EM, Rosenkrands I et al (2008) Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 3(9):e3116
2. Agrawal B, Krantz MJ et al (1998) Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol 10(12):1907-1916
3. Andersen CAS, Rosenkrands I et al (2009) Novel generation mycobacterial adjuvant based on liposome-encapsulated monomycoloyl glycerol from mycobacterium bovis bacillus calmetteguérin. J Immunol 183:2294-2302
4. Arora A, Prausnitz MR et al (2008) Micro-scale devices for transdermal drug delivery. Int J Pharm 364(2):227-236
5. Bakouche O, Gerlier D (1986) Enhancement of immunogenicity of tumour virus antigen by liposomes: the effect of lipid composition. Immunology 58:507-513
6. Ben Haij N, O Mzoughi, et al (2012) Cationic nanoglycolipidic particles as vector and adjuvant for the study of the immunogenicity of SIV Nef protein. Int J Pharm 423(1):116-123
7. Bernstein DI, Farley N et al (2010) The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 28:3748-3753
8. Bhowruth V, Minnikin DE et al (2009) Adjuvant properties of a simplified C32 monomycolyl glycerol analogue. Bioorg Med Chem Lett 19:2029-2032
9. Calcagnile S, Zuccotti G (2008) The virosomal adjuvanted influenza vaccine. Expert Opin Biol Ther 10(2):191-200
10. Cevc G, Vierl U (2010) Nanotechnology and the transdermal route. A state of the art review and critical appraisal. J Control Release 141:277-299
11. Chadwick S, Kriegel C et al (2010) Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 62(4-5):394-407
12. Chen W, Yan W et al (2008) A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother 57:517-530
13. Cheng J-Y, Huang H-N et al (2009) Transcutaneous immunization by lipoplex-patch based DNA vaccines is effective vaccination against japanese encephalitis virus infection. J Control Release 135:242-249
14. Christensen D, Foged C et al (2010) CAF01 liposomes as a mucosal vaccine adjuvant: in vitro and in vivo investigations. Int J Pharm 390:19-24
15. Christensen D, Korsholm KS et al (2007) Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 6(5):785-796
16. Gall D (1966) The adjuvant activity of aliphatic nitrogenous bases. Immunology 11:369-386
17. Garçon N, Chomez P et al (2007) GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6(5):723-739
18. Hansen J, Jensen KT et al (2008) Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J Infect Dis 198:758-767
19. Henriksen-Lacey M, Bramwell VW et al (2009) Liposomes based on dimethyldioctadecy-lammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 142(2):180-186
20. Henriksen-Lacey M, A Devitt, et al (2011) The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release 154(2):131-137
21. Hiszczyńska-Sawicka E, Li H et al (2010) Comparison of immune response in sheep immunized with DNA vaccine encoding Toxoplasma gondii GRA7 antigen in different adjuvant formulations. Exp Parasitol 124:365-372
22. Ishii KJ, Koyama S et al (2008) Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 3:352-363
23. Jacquet A, Vanderschrick J-F et al (2006) Vaccination with the recombinant allergen ProDer p 1 complexed with the cationic lipid DiC14-amidine prevents allergic responses to house dust mite. Mol Ther 11(6):960-968
24. Johansen P, Mohanan D et al (2010) Lympho-geographical concepts in vaccine delivery. J Control Release 148(1):56-62
25. Joseph A, Itskovitz-Cooper N et al (2006) A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS): i. immunogenicity and efficacy studies in mice. Vaccine 24(18):3990-4006
26. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5):373-384
27. Kirby C, Gregoriadis G (1984) Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnol 2:979-984
28. Kufer TA, Sansonetti PJ (2011) NLR functions beyond pathogen recognition. Nat Immunol 12 (2):121-128
29. Lay M, Callejo B et al (2009) Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone®) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 27:3811-3820
30. Logue CH, Phillips AT et al (2010) Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge. Antiviral Res 87:195-203
31. Lonez C, Lensink MF et al (2009) Cationic lipids activate cellular cascades. Which receptors are involved? Biochim Biophys Acta 1790(6):425-430
32. Mannock DA, Lee MYT et al (2008) Comparative calorimetric and spectroscopic studies of the effects of cholesterol and epicholesterol on the thermotropic phase behaviour of dipalmitoylphosphatidylcholine bilayer membranes. Biochim Biophys Acta 1778 (10):2191-2202
33. Mohanan D, Slütter B et al (2010) Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 147(3):342-349
34. Morrey JD, Motter NE et al (2011) Breaking B and T cell tolerance using cationic lipid-DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV. Antiviral Res 90(3):227-230
35. Nakano Y, Mori M et al (2002) Cholesterol inclusion in liposomes affects induction of antigen-specific IgG and IgE antibody production in mice by a surface-linked liposomal antigen. Bioconjug Chem 13:744-749
36. Neutra M, Kozlowski P (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6:148-158
37. Nordly P, Rose F et al (2011) Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J Control Release 150(3):307-317
38. O'Hagan DT, Gregorio ED (2009) The path to a successful vaccine adjuvant-the long and winding road. Drug Discov Today 14(11/12):541-551
39. Perrie Y, Rades T (2012) FASTtrack: pharmaceutics-drug delivery and targeting. Second Edition. London: Pharmaceutical Press
40. Pestano LA, B. Christian, et al. (2011). ONT-10, a liposomal vaccine targeting hypoglycosylated MUC1, induces a potent cellular and humoral response and suppresses the growth of MUC1 expressing tumors. Proceedings of the 102nd annual meeting of the american association for cancer research. Orlando, Florida, Philadelphia (PA): AACR
41. Sharp FA, Ruane D et al (2009) Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 160(3):870-875
42. Shrivastava S, Lole KS et al (2009) Development of candidate combination vaccine for hepatitis E and hepatitis B: a liposome encapsulation approach. Vaccine 27:6582-6588
43. Sullivan SM, Doukas J et al (2010) Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv 7(12):1433-1446
44. Tanaka T, Legat A et al (2008) DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur J Immunol 38:1-17
45. Thomann J-S, Heurtault B et al (2011) Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 32(20):4574-4583
46. Troyer RM, Propst KL et al (2009) Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine 27:4424-4433
47. van Houte AJ, Snippe H et al (1981) Characterization of immunogenic properties of haptenated liposomal model membranes in mice. V. Effect of membrane composition on humoral and cellular immunogenicity. Immunology 44(3):561-568
48. Voltan R, Castaldello A et al (2009) Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice. Vaccine 27(33):4498-4507
49. Wang D, Xu J et al (2010) Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response. Vaccine 28:3134-3142
50. Yan W, Huang L (2009) The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. Int J Pharm 368:56-62
51. Zhong Z, Wei X et al (2010) A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice. Int J Pharm 399(1-2):156-162